Construction, purification, and immunogenicity of recombinant cystein-cystein type chemokine receptor 5 vaccine

Protein Expression and Purification

Volumn 49, Issue 1, 2006, Pages 108-113

  Wu, Kongtian ^a,b   Xue, Xiaochang ^a,b   Wang, Zenglu ^a,b   Yan, Zhen ^a,b   Shi, Jihong ^a,b   Han, Wei ^a,b   Zhang, Yingqi ^a,b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b State Key Laboratory of Cancer Biology   (China)

Author keywords

CCR5; PADRE; Peptide vaccine; Protein purification

Indexed keywords

ANTIBODY; CHEMOKINE RECEPTOR CCR5;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MOUSE; VACCINATION;

ANIMALS; ANTIBODIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED BALB C; RECEPTORS, CCR5; VACCINATION;

ESCHERICHIA COLI; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33748041977     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2006.02.020     Document Type: Article

References (26)

1. Ostrowski M.A., Justement S.J., Catanzaro A., Hallahan C.A., Ehler L.A., Mizell S.B., Kumar P.N., Mican J.K., Chun T.W., and Fauci A.S. Expression of chemokine receptors CXCR4 and CCR5 in HIV-1-infected and uninfected individuals. J. Immunol. 161 (1998) 3195-3201
2. Sallusto F., Lenig D., Mackay C.R., and Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J. Exp. Med. 187 (1998) 875-883
3. Sallusto F., Schaerli P., Loetscher P., Schaniel C., Lenig D., Mackay C.R., Qin S., and Lanzavecchia A. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur. J. Immunol. 28 (1998) 2760-2769
4. Combadiere C., Ahuja S.K., Tiffany H.L., and Murphy P.M. Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1(alpha), MIP-1(beta), and RANTES. J. Leukoc. Biol. 60 (1996) 147-152
5. Raport C.J., Gosling J., Schweickart V.L., Gray P.W., and Charo I.F. Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1β, and MIP-1. J. Biol. Chem. 271 (1996) 17161-17166
6. Samson M., Labbe O., Mollereau C., Vassart G., and Parmentier M. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 35 (1996) 3362-3367
7. Oppermann M. Chemokine receptor CCR5: insights into structure,function, and regulation. Cell. Signal. 16 (2004) 1201-1210
8. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., Di Marzio P., Marmon S., Sutton R.E., Hill C.M., Davis C.B., Peiper S.C., Schall T.J., Littman D.R., and Landau N.R. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381 (1996) 661-666
9. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 381 (1996) 667-673
10. Berger E.A., Murphy P.M., and Farber J.M. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17 (1999) 657-700
11. Kootstra N.A., Mulder-Kampinga G.A., Albrecht-van Lent N., Scherpbier H.J., Veenstra J., Boer K., Coutinho R.A., Miedema F., and Schuitemaker H. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J. Clin. Inves. 94 (1994) 2060-2067
12. Roda Husman A.M., van Rij R.P., Blaak H., Broersen S., and Schuitemaker H. Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression. J. Infect. Dis. 180 (1999) 1106-1115
13. Dean M., Carrington M., Winkler C., Huttley G.A., Smith M.W., Allikmets R., Goedert J.J., Buchbinder S.P., Vittinghoff E., Gomperts E., Donfield S., Vlahov D., Kaslow R., Saah A., Rinaldo C., Detels R., and O'Brien S.J. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273 (1996) 1856-1862
14. Koot M., Cornelissen M., Keet I.P., Brouwer M., Broersen S.M., Bakker M., Roos M.T., Prins M., de Wolf F., Coutinho R.A., Miedema F., Goudsmit J., and Schuitemaker H. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann. Intern. Med. 127 (1997) 882-890
15. Liu R., Paxton W.A., Choe S., Ceradini D., Martin S.R., Horuk R., MacDonald M.E., Stuhlmann H., Koup R., and Landau N. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply exposed individuals to HIV-1 infection. Cell 86 (1996) 367-377
16. Smith M.W., Dean M., Carrington M., Winkler C., Huttley G.A., and Lomb D.A. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 277 (1997) 959-965
17. Arteaga H., Hinkula J., Van Dijk-Hard I., Dilber M.S., Wahren B., Christensson B., Mohamed A.J., and Edvard Smith C.I. Choosing CCR5 or Rev siRNA inHIV-1. Nat. Biotechnol. 21 (2003) 230-231
18. Baba M., Nishimura O., Kanzaki N., Okamoto M., Sawada H., Iizawa Y., Shiraishi M., Aramaki Y., Okonogi K., Ogawa Y., Meguro K., and Fujino M. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. USA 96 (1999) 5698-5703
19. Qin X.F., An D.S., Chen I.S., and Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc. Natl. Acad. Sci. USA 100 (2003) 183-188
20. Trkola A., Ketas T.J., Nagashima K.A., Zhao L., Cilliers T., Morris L., Moore J.P., Maddon P.J., and Olson W.C. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J. Virol. 75 (2001) 579-588
21. del Guercio M.F., Alexander J., Kubo R.T., Arrhenius T., Maewal A., Appella E., Hoffman S.L., Jonse T., Valmori D., Sakacuchi K., Gray H.M., and Sette A. Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo. Vaccine 15 (1997) 441-448
22. L promoter. Chin. J. Virol. 6 (1990) 111-116
23. Agrawal L., VanHorn-Ali Z., Berger E.A., and Alkhatib G. Specific inhibition of HIV-1 coreceptor activity by synthetic peptides corresponding to the predicted extracellular loops of CCR5. Blood 103 (2004) 1211-1217
24. Winkler M.E., Blaber M., Bennett G.L., Holmes W., and Vehar G.A. Purification and characterization of recombinant urokinase from Escherichia coli. Biotechnology (NY) 3 (1985) 990-1000
25. Amons R., and Schrier P.I. Removal of sodium dodecyl sulfate from proteins and peptides by gel filtration. Anal. Biochem. 116 (1981) 439-443
26. Marston F.A., Lowe P.A., Doel M.T., Schoemaker J.M., White S., and Angal S. Purification of calf prochymosin (prorennin) synthesized in Escherichia coli. Biotechnology (N Y) 2 (1984) 800-804